Stem Cell Migration via Cancer Medium Education
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using nano-scale anti-cancer drugs face challenges such as high costs due to low cancer-targeting ability of stem cells, requiring large quantities, and side effects from conventional chemotherapy and targeted therapies.
Innovation Solution
Enhancing the migration ability of stem cells into cancer cells by treating them with a cell culture medium from cancer patients and anion channel activators, forming a stem cell-nano anti-cancer drug complex with carbon nanotubes or gold nanoparticles loaded with anti-cancer drugs, and administering them therapeutically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are used as drug delivery vehicles for nano-scale anti-cancer drugs, then cancer targeting ability is improved, but the cost increases due to requiring large quantities of stem cells
Solution Approach 1:
The patent applies parameter changes by modifying the surface properties of stem cells through co-cultivation with cancer cells and treatment with anion channel activators. This education process alters the chemokine receptor expression and migration capabilities of stem cells, enabling them to target cancer cells more effectively. As a result, fewer stem cells are needed to achieve the same targeting efficiency, thereby reducing costs while maintaining or improving cancer targeting ability.
2Reliability
If conventional chemotherapy drugs are used to treat cancer, then cancer cells are killed, but side effects increase due to attacking normally dividing cells
Solution Approach 1:
The patent uses stem cells as intermediary carriers to deliver nano-scale anti-cancer drugs directly to cancer cells. The stem cells act as mediators that navigate the body's systems and release the drug payload specifically at the tumor site. This approach eliminates the need for conventional chemotherapy to attack all dividing cells, as the delivery system is guided by the stem cell's migration capabilities toward cancer cells alone, thereby reducing side effects while maintaining cancer killing effectiveness.
Solution Approach 2:
The patent replaces the mechanical system of conventional chemotherapy (which relies on non-specific cell cycle disruption) with a biological guidance system based on stem cell migration and chemokine signaling. The stem cells use their inherent ability to respond to chemokine gradients to navigate to cancer cells, substituting the brute-force approach of chemotherapy with a targeted biological delivery mechanism that spares normal cells.
3Reliability
If targeted anti-cancer drugs are developed for specific cancer types, then treatment specificity is improved, but resistance develops over time requiring long-term administration
Solution Approach 1:
The patent creates a universal delivery platform using stem cells that can be educated to target different types of cancer cells through co-cultivation with various cancer cell lines. The stem cells acquire cancer-type-specific migration capabilities during the education process, enabling a single stem cell population to adapt to and target multiple cancer types. This multi-functionality allows for flexible treatment protocols that may reduce the need for long-term administration of specific targeted drugs, as the stem cell-based system can be reconfigured for different cancer types.
Data Source
AI summary
The present invention relates to a method for improving the migration ability of stem cells into cancer cells comprising educating the stem cells by treating the stem cells with an in vitro cell culture medium of cancer cells obtained from a cancer patient to be treated and optionally an anionic channel activator.